SCHEMBL12419554

SCHEMBL12419554

CCCCc1nnc(-c2ccc(B(O)O)cc2)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
DDX3X O00571 1/20 0.47
LPL P06858 5/20 0.45
LIPG Q9Y5X9 5/20 0.45
TRPV1 Q8NER1 1/20 0.44
MGLL Q99685 1/20 0.44
DGAT1 O75907 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
SPHK1 Q9NYA1 1/20 0.41
TSHR P16473 3/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
NOTUM Q6P988 1/20 0.41
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12419524 0.96 LPL (0.51) MAPTCA1CA2DDX3XLPL
SCHEMBL12419540 0.94 LPL (0.53) MAPTCA1CA2DDX3XLPL
SCHEMBL12419544 0.91 MAPT (0.61) MAPTCA1CA2DDX3XLPL
SCHEMBL12419543 0.85 MAPT (0.42) MAPTDDX3XNR1H4TSHRUSP2
SCHEMBL12420283 0.84 MAPT (0.45) MAPTLPLLIPGNR1H4TSHR
SCHEMBL12420278 0.84 MAPT (0.42) MAPTCA1CA2DDX3XDGAT1
SCHEMBL16487849 0.83 NR1H4 (0.48) MAPTDDX3XNR1H4NOTUMKDM4E
SCHEMBL12419606 0.82 NOTUM (0.46) MAPTCA1CA2NR1H4TSHR
SCHEMBL12419546 0.82 USP2 (0.41) MAPTCA1CA2DDX3XNR1H4
SCHEMBL12419599 0.82 HDAC3 (0.39) MAPTCA1CA2DDX3XNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MAPT 3395/4885CA1 822/4885CA2 1487/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MAPT 3395/4885CA1 822/4885CA2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.